Revisiting the global state of hyperkalaemia survey
Hyperkalaemia (HK), or elevated levels of potassium in the blood1, is a common condition among cardiorenal patients.2 Left untreated, HK可导致严重且可能危及生命的心血管并发症, including serious arrhythmias and cardiac arrest in severe cases. 1,3-4
In 2021, 澳门葡京赌博游戏开始更好地了解香港对慢性肾脏疾病(CKD)和心力衰竭(HF)患者的全球管理状况。. These efforts led to the global state of hyperkalaemia survey, which fielded to 1,000 patients with CKD and HK, and 500 healthcare providers (HCPs) across five countries.5
调查结果显示，约三分之二的CKD (n=654)和HF (n=233)患者不知道HK是其病情的潜在并发症，对疾病的常见症状认识较差.5 患者缺乏这种意识可能会对CKD或HF患者造成潜在的破坏性影响.
这项全球调查以及最近的研究表明，仍然迫切需要改善心肾患者高钾血症的护理选择, especially those who are being treated with RAASi therapy.7-8
高钾血症在心肾患者中的高患病率和显著负担
Patients with CKD and HF often experience HK.2,6 最近的研究强调在这一人群中管理HK的需求未得到满足，因为这种情况与发病率和死亡率增加有关.7
治疗HK的一种常见方法是让患者坚持低钾饮食. 然而，仅靠饮食调整往往不足以治疗慢性肾病患者的HK. 一项现实世界的证据研究显示，超过一半的患者(n=2,由于缺乏成功的干预措施，患有HK和3-4期CKD的患者在6个月内复发HK.*,9
肾素-血管紧张素-醛固酮系统抑制剂(RAASi)治疗可用于降低HF患者的死亡风险，减缓CKD进展，同时降低CKD患者的心血管(CV)事件.7 慢性肾病患者的RAASi治疗也与高钾血症的风险增加有关.8 然而，HK的诊断往往导致RAASi治疗的减少. Guidelines recommend the use of the highest tolerated RAASi dose, 但大多数心肾患者在HK事件后不会重新启动RAASi. Recent data shows that just 10-15% of US patients (n=25,963) and 6-8% of Japanese patients (8,722) restarted treatment within six months of an event. It is crucial to find proactive, holistic solutions for managing HK, 这就是为什么澳门葡京赌博游戏正在努力确保RAASi疗法能够维持下去的原因.10
优化护理，为高钾血症患者开启更美好的未来
During the 2023 European Renal Association congress, Ruud Dobber, Executive Vice-President, BioPharmaceuticals Business Unit, AstraZeneca, addressed the need for improved care options for patients with HK. 他指出:“未能实现指南指导的RAASi治疗可能对心肾患者产生严重后果, 然而，最近的研究强调，这些患者很少在高钾血症相关停药后恢复治疗, 迫切需要改变高血钾管理的实践来实现这一点. 澳门葡京赌博游戏致力于支持高钾血症的管理，并与医疗保健社区更广泛地合作，帮助为患者提供更好的心肾护理.”
为香港人开启更美好的未来，需要与医疗专业人士合作, patient advocacy groups, governments and policymakers. 这种协作可以改善获得医疗保健的途径，并改变检测方式, diagnosis, and treatment of HK and other CV and metabolic diseases.
At AstraZeneca, 澳门葡京赌博游戏正在努力改变数百万患有复杂CV的人的结局, renal, and metabolic (CVRM) diseases, and highlight their interconnection, including hyperkalaemia. 早期发现和护理对于改善患者预后和减轻慢性粒细胞增多症疾病及其相关风险和并发症的负担至关重要, healthcare systems, societies, and our planet.
Disclaimer: *Data from patient populations in the United States
You may also like
References:
1. National Kidney Foundation. What is Hyperkalemia? [cited 2023 June 26]. Available from: URL: http://www.kidney.org/atoz/content/what-hyperkalemia
2. Thomsen RW et al. Nephrol Dial Transplant. 2018;33(9):1610-1620;
3. Vallentin MF, Povlsen AL, Granfeldt A, Terkelsen CJ, Andersen LW. 钙对无脉电活动患者和可能与高钾血症和缺血相关的心电图特征的影响——钙治疗院外心脏骤停(COCA)试验的亚研究. Resuscitation. 2022;181:150-157.
4. Rossignol P, Legrand M, Kosiborod M, et al. 严重高钾血症的应急管理:最佳做法指南和未来的机遇. Pharmacol Res. 2016;113(pt A):585-591. doi:10.1016/j.phrs.2016.09.039
5. 全球高钾血症调查关键发现，REF-129958，澳门葡京网赌游戏制药有限公司. Veeva ID: Z4-38799. Date of preparation: October 2021
6. Furuland H, et al. BMC Nephrol 2018;19:211. PMID: 30134846
7. Kanda E, Rastogi A, Murohara T, et al. 高钾血症发作后次优RAASi治疗的临床影响. BMC Nephrol. 2023;24(1):18. doi:10.1186/s12882-022-03054-5
8. Santoro A, et al. 高钾血症、RAASi不依从性与慢性肾脏疾病结局之间的关系. J Nephrol. 2022;35(2):463-472. doi:10.1007/s40620-021-01070-6
9. Data on file, REF-178557, AZPLP
10. Kanda E et al. 高钾血症停药后再启动RAASi的次优程度:美国和日本心肾患者的观察性研究. Presented at: ERA 2023 Congress; 2023 June 15-18; Milan, Italy.
Veeva ID: Z4-55463
Date of preparation: July 2023